1-18 of 18
Johan Harmenberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Older Patients

Maria-Victoria Mateos, Pawel J. Robak, Laura Rosiñol, Argiris Symeonidis, Pieter Sonneveld, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Roman Hájek
Journal: Blood
Blood (2021) 138 (Supplement 1): 2741.
https://doi.org/10.1182/blood-2021-147005
Published: 2021
Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses

Paul G. Richardson, Fredrik H. Schjesvold, Haifaa Abdulhaq, Daniel Coriu, Antonio Lazzaro, Pieter Sonneveld, Torbjörn Kullenburg, Johan Harmenberg, Marcus Thuresson, Catriona Byrne, María-Victoria Mateos
Journal: Blood
Blood (2021) 138 (Supplement 1): 2732.
https://doi.org/10.1182/blood-2021-146863
Published: 2021
Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Subgroup Analysis By Prior Alkylator Exposed/Refractory Status

Pieter Sonneveld, Maria-Victoria Mateos, Pawel J. Robak, Fredrik H. Schjesvold, Roman Hajek, Paul G. Richardson, Johan Harmenberg, Marcus Thuresson, Catriona Byrne, Meletios-Athanasios Dimopoulos
Journal: Blood
Blood (2021) 138 (Supplement 1): 4779.
https://doi.org/10.1182/blood-2021-146844
Published: 2021
Journal Articles

OCEAN (OP-103): Melflufen Plus Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM) - Renal Impairment (RI) Analysis

Tadeusz Robak, Sosana Delimpasi, Ludek Pour, Tamas Masszi, Ivan Spicka, Wojciech Legiec, Pieter Sonneveld, Marcus Thuresson, Kajsa Larsson, Johan Harmenberg, Fredrik H. Schjesvold
Journal: Blood
Blood (2021) 138 (Supplement 1): 4777.
https://doi.org/10.1182/blood-2021-146550
Published: 2021
Journal Articles

HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) Exposed to Prior Alkylator Therapy-Subgroup Analysis

Paula Rodríguez-Otero, MD PhD, María-Victoria Mateos, MD PhD, Albert Oriol, Alessandra Larocca, Joan Blade Creixenti, Michele Cavo, Xavier Leleu, MD, Maxim Norkin, MD PhD, Omar Nadeem, MD, John W. Hiemenz, MD, Hani Hassoun, MD, Cyrille Touzeau, Adrián Alegre Amor, MD PhD, Agne Paner, MD, Christopher Maisel, MD, Amitabha Mazumder, MD, Anastasios Raptis, MD, Noemí Puig, MD PhD, Marcus Thuresson, PhD, Johan Harmenberg, MD PhD, Olof Harlin, VMD, PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-136466
Published: 2020
Journal Articles

HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Elderly Patients

Alessandra Larocca, Paul G. Richardson, MD, Albert Oriol, Joan Blade Creixenti, Michele Cavo, Paula Rodríguez-Otero, MD PhD, Xavier Leleu, MD, Maxim Norkin, MD PhD, Omar Nadeem, MD, John W. Hiemenz, MD, Hani Hassoun, MD, Cyrille Touzeau, Adrián Alegre Amor, MD PhD, Agne Paner, MD, Christopher Maisel, MD, Amitabha Mazumder, MD, Anastasios Raptis, MD, Noemí Puig, MD PhD, Marcus Thuresson, PhD, Johan Harmenberg, MD PhD, Bengt Gustavsson, Dr MDSci, MSc Pharm, María-Victoria Mateos, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–46.
https://doi.org/10.1182/blood-2020-136856
Published: 2020
Journal Articles

HORIZON (OP-106) Versus MAMMOTH: An Indirect Comparison of Efficacy Outcomes for Patients with Relapsed/Refractory Multiple Myeloma Refractory (RRMM) to Anti-CD38 Monoclonal Antibody Therapy Treated with Melflufen Plus Dexamethasone Versus Conventional Agents

Joan Blade Creixenti, María-Victoria Mateos, MD PhD, Albert Oriol, Alessandra Larocca, Michele Cavo, Paula Rodríguez-Otero, MD PhD, Xavier Leleu, MD, Maxim Norkin, MD PhD, Omar Nadeem, MD, John W. Hiemenz, MD, Hani Hassoun, MD, Cyrille Touzeau, Adrián Alegre Amor, MD PhD, Agne Paner, MD, Christopher Maisel, MD, Amitabha Mazumder, MD, Anastasios Raptis, MD, Noemí Puig, MD PhD, Stojan Zavisic, BSc, Marcus Thuresson, PhD, Johan Harmenberg, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–4.
https://doi.org/10.1182/blood-2020-137164
Published: 2020
Journal Articles

HORIZON (OP-106): Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics-Subgroup Analysis

María-Victoria Mateos, MD PhD, Albert Oriol, Alessandra Larocca, Joan Blade Creixenti, Michele Cavo, Paula Rodríguez-Otero, MD, Xavier Leleu, MD, Maxim Norkin, MD PhD, Omar Nadeem, MD, John W. Hiemenz, MD, Hani Hassoun, MD, Cyrille Touzeau, Adrián Alegre Amor, MD PhD, Agne Paner, MD, Christopher Maisel, MD, Amitabha Mazumder, MD, Anastasios Raptis, MD, Noemí Puig, MD PhD, Johan Harmenberg, MD PhD, Bengt Gustavsson, Dr MDSci, MSc Pharm, Marcus Thuresson, PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–43.
https://doi.org/10.1182/blood-2020-136002
Published: 2020
Journal Articles

HORIZON (OP-106): Melflufen Plus Dexamethasone (dex) in 55 Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD)-Subgroup Analysis

Paul G. Richardson, MD, María-Victoria Mateos, MD PhD, Albert Oriol, Alessandra Larocca, Michele Cavo, Paula Rodríguez-Otero, MD PhD, Xavier Leleu, MD, Maxim Norkin, MD PhD, Omar Nadeem, MD, John W. Hiemenz, MD, Hani Hassoun, MD, Cyrille Touzeau, Adrián Alegre Amor, MD PhD, Agne Paner, MD, Christopher Maisel, MD, Amitabha Mazumder, MD, Anastasios Raptis, MD, Noemí Puig, MD PhD, Elena Zamagni, Marcus Thuresson, PhD, Johan Harmenberg, MD PhD, Olof Harlin, VMD, PhD, Joan Blade Creixenti
Journal: Blood
Blood (2020) 136 (Supplement 1): 15–17.
https://doi.org/10.1182/blood-2020-137118
Published: 2020
Journal Articles

Updated Progression-Free Survival (PFS) and Overall Survival (OS) with Melflufen and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 2 Study O-12-M1

Sara Bringhen, Peter M. Voorhees, MD, Torben Plesner, MD DSc, Ulf-Henrik Mellqvist, MD PhD, Brandi Reeves, MD, Pieter Sonneveld, Catriona Byrne, RN, Eva Nordström, MSc, Johan Harmenberg, MD PhD, Jakob Obermüller, MSc, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1839.
https://doi.org/10.1182/blood-2019-124828
Published: 2019
Journal Articles

The Burden of Relapsed/Refractory Multiple Myeloma: An Indirect Comparison of Health-Related Quality of Life Burden across Different Types of Advanced Cancers at Baseline and after Treatment Based on HORIZON (OP-106) Study of Melflufen Plus Dexamethasone

Paul G. Richardson, MD, Alessandra Larocca, Xavier Leleu, MD PhD, Albert Oriol, MD, Agne Paner, MD, Paula Rodriguez Otero, Cyrille Touzeau, MD, Adrián Alegre Amor, MD, Christopher Maisel, MD, María-Victoria Mateos, MD PhD, Amitabha Mazumder, MD, Peter Strang, MD, Oskar Öhman, MSc, Johan Harmenberg, MD PhD, Stojan Zavisic, Joan Bladé, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3487.
https://doi.org/10.1182/blood-2019-124832
Published: 2019
Journal Articles

OP201: A Phase 1/2 Study of Melflufen and Dexamethasone in Patients with Immunoglobulin Light Chain (AL) Amyloidosis

Giovanni Palladini, MD PhD, Stefan O. Schönland, MD, Suzanne Lentzsch, MD PhD, M. Teresa Cibeira, MD PhD, Roman Hajek, Prof, MD PhD, Arnaud Jaccard, MD PhD, Krzysztof Jamroziak, MD PhD, Eftathios Kastritis, Vaishali Sanchorawala, MD, Fredrik H. Schjesvold, MD PhD, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM, Sara Thuresson, MSc, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Giampaolo Merlini, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3163.
https://doi.org/10.1182/blood-2019-124244
Published: 2019
Journal Articles

Clinical Activity of Melflufen in Patients with Triple-Class Refractory Multiple Myeloma and Poor-Risk Features in an Updated Analysis of HORIZON (OP-106), a Phase 2 Study in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Pomalidomide and/or Daratumumab

María-Victoria Mateos, MD PhD, Albert Oriol, MD, Alessandra Larocca, Paula Rodriguez Otero, Joan Bladé, MD, Michele Cavo, Hani Hassoun, MD, Xavier Leleu, MD PhD, Adrián Alegre Amor, MD, Christopher Maisel, MD, Agne Paner, MD, Johan Harmenberg, MD PhD, Catriona Byrne, RN, Sara Thuresson, MSc, Hanan Zubair, MSc, Paul G. Richardson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1883.
https://doi.org/10.1182/blood-2019-124825
Published: 2019
Journal Articles

OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS

Paul Richardson, Enrique Ocio, MD, Albert Oriol, MD, Alessandra Larocca, MD, Paula Rodriguez Otero, MD, Jan Moreb, MD, Joan Bladé, MD, Hani Hassoun, MD, Michele Cavo, MD, Adrián Alegre, MD, Amitabha Mazumder, MD, Christopher Maisel, MD, Agne Paner, MD, Nashat Gabrail, MD, Jeffrey A Zonder, MD, Dharminder Chauhan, PhD, Johan Harmenberg, MD, Sara Thuresson, MSc, Hanan Zubair, MSc, Maria-Victoria Mateos, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 600.
https://doi.org/10.1182/blood-2018-99-113095
Published: 2018
Journal Articles

First Report on Overall Survival (OS) and Improved Progression Free Survival (PFS) in a Completed Phase 2a Study of Melflufen in Advanced Relapsed Refractory Multiple Myeloma (RRMM)

Paul G Richardson, MD, Sara Bringhen, MD, Peter M. Voorhees, MD, Torben Plesner, MD, Claudia Paba-Prada, MD, Ulf-Henrik Mellqvist, MD, Jeffrey A Zonder, MD, Brandi Reeves, MD, Antonio Palumbo, MD, Catriona Byrne, RN, Johan Harmenberg, MD PhD, Eva Nordstrom, MSc, MBA, Hanan Zubair, MSc, Jakob Lindberg, MD PhD, Pieter Sonneveld, MDPhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3150.
https://doi.org/10.1182/blood.V130.Suppl_1.3150.3150
Published: 2017
Journal Articles

Melflufen Therapy for Relapsed Refractory Multiple Myeloma (RRMM) Patients Refractory to Daratumumab and/or Pomalidomide: A Report on Early Efficacy

Maria-Victoria Mateos, MD, Joan Bladé, MD PhD, Alessandra Larocca, Albert Oriol, MD, Paula Rodriguez, MD, Adrián Alegre, MD, Michele Cavo, MD, Jan S Moreb, MD, Agne Paner, MD, Nashat Gabrail, MD, Kathleen G. Halka, MD, Hani Hassoun, MD, Christopher Maisel, MD, Amitabha Mazumder, MD, Jeffrey A Zonder, MD, Enrique M Ocio, MD, Catriona Byrne, RN, Johan Harmenberg, MD PhD, Sara Thuresson, MSc, Eva Nordstrom, MSc, MBA, Jakob Lindberg, MD PhD, Paul G Richardson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1841.
https://doi.org/10.1182/blood.V130.Suppl_1.1841.1841
Published: 2017
Journal Articles

Efficacy of Melflufen, a Peptidase Targeted Therapy, and Dexamethasone in an Ongoing Open-Label Phase 2a Study in Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM) Including an Initial Report on Progression Free Survival

Peter M. Voorhees, MD, Valeria Magarotto, MD, Pieter Sonneveld, MD PhD, Torben Plesner, MD, Ulf-Henrik Mellqvist, MD PhD, Claudia E. Paba-Prada, MD, Catriona Byrne, RN, Johan Harmenberg, MDPhD, Eva Nordstrom, MSc,MBA, Antonio Palumbo, MD, Paul Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 3029.
https://doi.org/10.1182/blood.V126.23.3029.3029
Published: 2015
Journal Articles

Determination of the MTD and Encouraging Results in an Ongoing Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination for Patients with Relapsed and Relapsed-Refractory Multiple Myeloma (RRMM)

Claudia Paba-Prada, MD, Antonio Palumbo, MD, Ulf-Henrik Mellqvist, MD PhD, Peter M Voorhees, MD, Torben Plesner, MD, Pieter Sonneveld, MD, Catriona Byrne, RN, Johan Harmenberg, MDPhD, Eva Nordstrom, MSc,MBA, Paul G. Richardson
Journal: Blood
Blood (2014) 124 (21): 2123.
https://doi.org/10.1182/blood.V124.21.2123.2123
Published: 2014